Announcements Trials
Browse Landscape

Phase

Phase 2 44Phase 3 8Phase 1 5Phase NA 3Phase 1/2 2Phase 4 1Phase 2/3 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2CNS 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1HER2-expressing Advanced Solid Tumors 1HER2 Positive Metastatic Breast Cancer 1HER-2 Positive Colorectal Cancer 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Metastatic 1Brain Neoplasms 1

Interventions

Trastuzumab 61Paclitaxel 57Cyclophosphamide 44pembrolizumab 35Fulvestrant 34Capecitabine 29Carboplatin 27Docetaxel 23Letrozole 22Doxorubicin 19palbociclib 16abemaciclib 16pertuzumab 14durvalumab 14Filgrastim 13Everolimus 13ribociclib 12Lapatinib 12Gemcitabine 12exemestane 11eribulin 11Vinorelbine 11Albumin-Bound Paclitaxel 11Bevacizumab 10trastuzumab deruxtecan 9neratinib 9fludarabine 9Taxes 9Radiotherapy 9Peripheral Blood Stem Cell Transplantation 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Breast Neoplasms × pyrotinib × Clear all
NCT03772353 2023-03-07

PLEASURABLE

Fudan University

Phase 1/2 Unknown
59 enrolled
Breast

Breast Neoplasms

NCT04582968 2023-01-18

Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases

Fudan University

Phase 1/2 Unknown
39 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡